3-((((1-METHYLETHOXY)CARBONYL)OXY)METHOXY)MORPHINAN, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H29NO4
Molecular Weight	359.4593
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of 3-((((1-METHYLETHOXY)CARBONYL)OXY)METHOXY)MORPHINAN, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

Structure Search

SMILES

CC(C)OC(=O)OCOC1=CC2=C(C[C@@H]3NCC[C@]24CCCC[C@H]34)C=C1

InChI

InChIKey=XUUSKRFBAUMDGN-LMNJBCLMSA-N

InChI=1S/C21H29NO4/c1-14(2)26-20(23)25-13-24-16-7-6-15-11-19-17-5-3-4-8-21(17,9-10-22-19)18(15)12-16/h6-7,12,14,17,19,22H,3-5,8-11,13H2,1-2H3/t17-,19+,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H29NO4
Molecular Weight	359.4593
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:40:24 GMT 2025` Edited by `admin` on `Tue Apr 01 16:40:24 GMT 2025`
Record UNII	2P8DBQ9WL3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GCC-1290K

Preferred Name

English

3-((((1-METHYLETHOXY)CARBONYL)OXY)METHOXY)MORPHINAN, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

Systematic Name

English

MORPHINAN, 3-((((1-METHYLETHOXY)CARBONYL)OXY)METHOXY)-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

Systematic Name

English

(9.ALPHA.,13.ALPHA.,14.ALPHA.)-3-((((1-METHYLETHOXY)CARBONYL)OXY)METHOXY)MORPHINAN

Systematic Name

English

Code System Code Type Description

PUBCHEM

46213529

Created by admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025

PRIMARY

CAS

1058185-02-6

Created by admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025

PRIMARY

FDA UNII

2P8DBQ9WL3

Created by admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025

PRIMARY

Related Record Type Details


					2P8DBQ9WL3

3-((((1-METHYLETHOXY)CARBONYL)OXY)METHOXY)MORPHINAN, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

ACTIVE MOIETY

Comments:

Green Cross, under license from Kangwon University Pharmaceutical College, is developing GCC-1290K (GC-2101), an oral small molecule dopamine modulator and lead from a series of prodrugs of (+)-3-hydroxymorphinan (3-HM), for the potential treatment of Parkinson's disease. 3-HM is the active compound with a potent neuroprotective activity and a good safety profile. The molecule effectively blocks the degeneration of dopaminergic cells in animal models. In February 2010 the FDA accepted the IND for this molecule. Phase I study was completed in 2011 and commercialization was expected in 2015. The global anti-Parkinson`s drug market is expected to reach $3 billion US in 2013. In Korea, approximately 70,000 patients have Parkinson`s disease.